Retatrutide vs Semaglutide: Trial Data and Status

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide vs Ozempic and Wegovy comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, Laura, a 46-year-old project manager in Denver, showed up to her quarterly telehealth check-in with a printout of a Reddit thread comparing retatrutide to semaglutide. She'd been on compounded semaglutide for five months, was down 31 pounds, and wanted to know if she should "wait for the better drug." Her prescriber, an obesity medicine physician who sees roughly 200 GLP-1 patients a month, told her something she didn't expect: "The comparison you're making isn't the one that matters right now. One of these drugs exists. The other one doesn't, not yet."

That exchange captures the central tension of the retatrutide vs semaglutide question in 2026. There's enough published trial data to make the comparison feel concrete. But the practical reality for patients is more lopsided than the numbers suggest.

This guide sits inside the broader Compounded Semaglutide vs Ozempic and Wegovy cluster, which is part of the compounded semaglutide pillar guide.

Two Molecules, Very Different Timelines

Start with what each drug actually is.

Semaglutide is a GLP-1 receptor agonist. It's the active ingredient in Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management in eligible patients). Both are manufactured by Novo Nordisk. Same molecule, different dose ceilings, different labeled indications.

Compounded semaglutide uses that same active ingredient, prepared by a licensed compounding pharmacy under a patient-specific clinician prescription. It is not FDA-approved. The clinical evidence for the molecule comes from trials conducted with the branded forms. Compounded preparations have not undergone equivalent randomized trials.

Retatrutide is something different. Developed by Eli Lilly, it's an investigational triple agonist that hits three receptors: GLP-1, GIP, and glucagon. That third target, the glucagon receptor, is what distinguishes it from older incretin therapies. As of mid-2026, retatrutide has completed Phase 2 weight management trials with striking reported weight loss, and Phase 3 trials are ongoing. It is not FDA-approved. You cannot get it prescribed. There is no compounded version. It is, for practical purposes, a clinical trial entry on clinicaltrials.gov and a collection of published Phase 2 results.

Here's the thing: comparing retatrutide's Phase 2 data to semaglutide's completed Phase 3 program is a little like comparing a college quarterback's combine stats to a ten-year NFL starter's career record. The numbers are interesting. They are not yet the same kind of evidence.

The Semaglutide Evidence Base, Briefly

The trial program behind semaglutide is one of the most extensive for any obesity medication in history. A few anchors:

STEP-1 tested 2.4 mg weekly semaglutide against placebo over 68 weeks. The active arm reported mean weight loss of 14.9 percent from baseline. This is the number most commonly cited in patient-facing materials, and it's a mean, not a guarantee for any individual.

STEP-3 layered a structured lifestyle intervention (intensive behavioral therapy, meal replacements, physical activity targets) on top of the same protocol. Mean weight loss was higher. The implication is straightforward: the drug and lifestyle changes are additive. Lifestyle isn't optional if you want durable results.

STEP-4 is the trial that tends to get less attention but matters more for long-term planning. Participants who switched from active drug to placebo at week 20 experienced partial weight regain over the following 48 weeks. The chronic biology of weight regulation doesn't forget. This is consistent with how other chronic conditions behave when you withdraw treatment.

SELECT, completed in 2023, reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes. That's a cardiovascular outcome trial, not a weight-loss trial, and it changed the clinical calculus for a lot of prescribers.

SUSTAIN-6 and LEADER anchor the cardiovascular safety profile for the broader GLP-1 class.

Where the Retatrutide Data Stands

The Phase 2 data for retatrutide generated genuine excitement among obesity medicine specialists, and for good reason. The reported weight-loss figures at higher doses were substantially above what semaglutide delivered in STEP-1.

But Phase 2 trials are designed to test safety, tolerability, and dose-finding. They use selected patient populations, tightly controlled protocols, and relatively small sample sizes. Phase 3 trials, with larger and more diverse populations, frequently produce more modest (and more realistic) effect sizes. This is not speculation. It's the historical pattern for obesity drugs.

My honest assessment: retatrutide's triple-agonist mechanism is genuinely novel, and the glucagon receptor activity may offer metabolic advantages (particularly around hepatic fat reduction) that GLP-1-only drugs don't. But calling it a better drug than semaglutide right now would be premature. We don't have Phase 3 completion, we don't have real-world durability data, we don't have a cardiovascular outcomes trial. We have promising early returns.

I'm not predicting the regulatory trajectory. Neither should anyone else.

What Patients Actually Need to Decide

For anyone currently evaluating their options, the retatrutide vs semaglutide comparison mostly collapses into a simpler question: what's available to me right now, and how do I use it well?

Three factors drive the decision between branded and compounded semaglutide:

Access and cost. Branded Wegovy and Ozempic require either insurance coverage or near-list-price out-of-pocket payment. Compounded semaglutide operates under a different cost structure but without FDA approval. For many patients, this is the deciding factor and the conversation stops here.

Dose flexibility. Compounded programs can adjust dosing in ways that pre-filled pens cannot. Some clinicians value the ability to titrate in smaller increments, particularly for patients with pronounced GI side effects early in treatment.

Clinical context. A patient with type 2 diabetes, established cardiovascular disease, and an indication supported by SELECT has a different clinical calculus than a patient seeking weight management without metabolic comorbidities. The branded products carry FDA-approved indications for specific populations. Compounded preparations do not.

The clinician relationship matters more than the brand. A program that responds to side effects with appropriate dose adjustments, provides clear follow-up between refills, and supports honest clinical conversation will outperform a flashier program with weaker infrastructure behind the scenes.

Four Misconceptions That Keep Coming Up

"Compounded semaglutide is basically the same thing as Wegovy." The active ingredient is the same. The regulatory status, manufacturing oversight, and evidence base are not. Compounding pharmacies operate under a different framework (503A or 503B), with different oversight. Treating them as interchangeable misreads the situation. So does treating compounded forms as categorically inferior. The active molecule is the same molecule.

"Worse nausea means the drug is working harder." Trial data don't support this. In STEP-1 and STEP-3, patients with mild GI tolerability and patients with more pronounced GI symptoms both achieved meaningful weight loss. Side effect intensity is not a proxy for efficacy.

"The medication does the work." STEP-3's results argue otherwise. Adding a structured lifestyle intervention to the same drug protocol produced greater mean weight loss than STEP-1, which used medication alone. The boring truth is that the drug reduces appetite and caloric intake, and what you do with the remaining calories (protein prioritization, resistance training, sleep quality) still matters. It arguably matters more on therapy, because when total intake is reduced, every calorie carries more nutritional weight.

"If I stop the drug, I'll just maintain." STEP-4 documented what happens: partial regain. Weight regulation is a chronic biological system. Withdrawing pharmacologic support allows it to reassert itself, the same way blood pressure climbs when you stop an antihypertensive. This isn't a failure of the drug. It's the nature of the condition.

So Should You Wait for Retatrutide?

No. Or, more precisely: not unless you're eligible for a clinical trial and your physician thinks it's appropriate.

Waiting for a drug that hasn't completed Phase 3 trials, hasn't received FDA approval, and has no established pricing, supply chain, or prescribing infrastructure means deferring treatment for a condition that compounds over time. Obesity is progressive. The metabolic consequences of delayed treatment aren't neutral.

If retatrutide is eventually approved and demonstrates the durability and safety profile its early data suggest, it will become another tool. A potentially important one. But the patients who will benefit most from retatrutide in 2028 or 2029 are likely the ones managing their weight effectively with available treatments right now.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide vs Ozempic and Wegovy cluster. For a broader treatment of the molecule, regulatory pathway, 503A and 503B compounding framework, and clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

Compounded semaglutide uses the same active ingredient, semaglutide. It is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. Wegovy and Ozempic are FDA-approved branded products manufactured by Novo Nordisk. Same molecule, different regulatory pathways and manufacturing standards.

What evidence applies across these forms?

The clinical trial evidence for semaglutide as a molecule comes from the SUSTAIN, STEP, and SELECT programs, all conducted with branded products. Compounded preparations have not undergone equivalent trials. The assumption in clinical practice is that the molecule behaves the same way, but the manufacturing and quality assurance processes differ.

Can patients switch between compounded and branded semaglutide?

Yes, but it's a clinical decision supervised by the prescriber. It depends on current dose, tolerability, and access. It's not something to do on your own between refills.

When will retatrutide be available?

There is no confirmed FDA approval date. Phase 3 trials are ongoing as of mid-2026. Even optimistic timelines place potential approval no earlier than late 2027 or 2028, with real-world availability potentially extending beyond that depending on manufacturing scale-up, pricing negotiations, and formulary decisions.

Is retatrutide better than semaglutide?

Phase 2 weight-loss figures were higher for retatrutide at top doses than semaglutide reported in Phase 3 trials. But cross-trial comparisons are unreliable, Phase 3 data are not yet complete, and there is no cardiovascular outcomes trial for retatrutide. "Better" is a conclusion the evidence doesn't yet support.

Should I stop semaglutide if retatrutide gets approved?

That's a conversation with your prescriber at the time, based on your response to current therapy, your risk profile, and what the retatrutide label and data look like at approval. There's no reason to plan around a hypothetical.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.